PERSPECTA

News from every angle

← Back to headlines

Arrowhead Pharmaceuticals Plans sNDA for SHASTA After Positive Trial Results

Arrowhead Pharmaceuticals announced plans to submit a supplemental New Drug Application (sNDA) for its drug SHASTA by the end of 2026, following trial results that showed significant triglyceride reductions and fewer pancreatitis events.

5 Aug, 00:42 — 5 Aug, 00:42
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed2h ago

Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events

Read full article →

Related Stories

Lifemate Furniture and Lomo Coffee Partner for Enhanced Customer Experience

4m ago

Insurance Premiums Fall for Two Years, Fires May Change Trend

7m ago

AkzoNobel Shareholders to Vote on Merger Plan

8m ago

UBS Sets GEK TERNA Stock Target Price at Up to 70 Euros

9m ago